1. Ahn DG, Shin HJ, Kim MH, et al. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19). J Microbiol Biotechnol. 2020;30(3):313-324. doi:10.4014/jmb.2003.03011
2. Zhang J, Wang X, Jia X, et al. Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767-772. doi:10.1016/j.cmi. 2020.04.012
3. Yu C, Lei Q, Li W, et al. Clinical characteristics, associated factors, and predicting COVID-19 mortality risk: a retrospective study in Wuhan, China. Am J Prev Med. 2020;59(2):168-175. doi:10.1016/j.amepre.2020.05.002
4. Cen Y, Chen X, Shen Y, et al. Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study.Clin Microbiol Infect. 2020;26(9):1242-1247. doi:10. 1016/j.cmi.2020.05.041
5. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
6. Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid chronic diseases are strongly correlated with disease severity among COVID-19 patients: a systematic review and meta-analysis.Aging Dis. 2020;11(3):668-678. doi:10.14336/AD.2020.0502
7. Banerjee A, Pasea L, Harris S, et al. Estimating excess 1-year mortality associated with the COVID-19 pandemic according to underlying conditions and age: a population-based cohort study.Lancet. 2020; 395(10238):1715-1725. doi:10.1016/S0140-6736(20)30854-0
8. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY.Nature. 2020;584(7821): 430-436. doi:10.1038/s41586-020-2521-4
9. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3
10. Satici C, Demirkol MA, Sargin Altunok E, et al. Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19.Int J Infect Dis. 2020;98:84-89. doi:10.1016/ j.ijid.2020.06.038
11. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.Clin Chem Lab Med. 2020;58(7):1021-1028. doi:10.1515/cclm-2020-0369
12. Güçlü E, Kocayiğit H, Okan HD, et al. Effect of COVID-19 on platelet count and its indices.Rev Assoc Med Bras (1992). 2020;66(8):1122-1127. doi:10.1590/1806-9282.66.8.1122
13. Ceyhan MA, Tümer M, Gürü S, Kadı G, Demir GG. Mean platelet volume and red cell distribution width values in patients with COVID-19 admitted to intensive care units or wards from emergency department. Archives Curr Med Res. 2021;2(2):88-92. doi:10.47482/acmr.2021.20
14. Li K, Wu J, Wu F, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia.Invest Radiol. 2020; 55(6):327-331. doi:10.1097/RLI.0000000000000672
15. Golcuk Y, Golcuk B, Bilge A, Irik M, Dikmen O. Combination of mean platelet volume and the CURB-65 score better predicts 28-day mortality in patients with community-acquired pneumonia.Am J Emerg Med. 2015;33(5):648-652. doi:10.1016/j.ajem.2015.02.001